Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

SummaryEarly stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   HER2-positive Breast Cancer Intervention:   Drug: [18F]FMISO PET/MRI imaging Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: CME/CNE Source Type: research
British Journal of Cancer, Published online: 02 April 2020; doi:10.1038/s41416-020-0815-9Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThe results of the BELIS study support that trastuzumab SC can be safely administered at home by a HCP and all patients considered this setting as beneficial. HCPs consider the SC formulation as the quickest method to administer trastuzumab.Trial registrationEudraCT Identifier: 2013-000123-13. ClinicalTrials.gov Identifier: NCT01926886.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Immutep reported positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha and paclitaxel in HER2-negative, HR-positive metastatic breast cancer (MBC).
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
PMID: 32218042 [PubMed - as supplied by publisher]
Source: The American Journal of Nursing - Category: Nursing Authors: Tags: Am J Nurs Source Type: research
AbstractBreast cancer is a disease of aging, and the incidence of breast cancer is projected to increase dramatically as the global population ages. The majority of breast cancers that occur in older adults are hormone-receptor positive, human epidermal growth factor receptor-2 (HER2)-negative phenotypes, with favorable tumor biology; yet, because of underrepresentation in clinical trials, less evidence is available to guide the complex care for this population. Providing care for older patients with metastatic breast cancer, with coexisting medical conditions, increased risk of treatment toxicity, and frailty, remains a c...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
AbstractBreast cancer is the leading killer of Chinese women. Immunohistochemistry index has great significance in the treatment strategy selection and prognosis analysis for breast cancer patients. Currently, histopathological examination of the tumor tissue through surgical biopsy is the gold standard to determine immunohistochemistry index. However, this examination is invasive and commonly causes discomfort in patients. There has been a lack of noninvasive method capable of predicting immunohistochemistry index for breast cancer patients. This paper proposes a machine learning method to predict the immunohistochemical ...
Source: Medical and Biological Engineering and Computing - Category: Biomedical Engineering Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Study